Patents by Inventor Lewis P. AMSEL

Lewis P. AMSEL has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MAZINDOL IR/SR MULTILAYER TABLET AND ITS USE FOR THE TREATMENT OF ATTENTION DEFICIT/HYPERACTIVITY DISORDER (ADHD)
    Publication number: 20220160639
    Abstract: The present invention relates to a modified-release composition of mazindol and its use in the treatment of attention deficit disorders (ADD) or attention deficit/hyperactivity disorder (ADHD) or related deficit of alertness (i.e., incoercible sleepiness) or decline of vigilance (i.e., daytime somnolence) or excessive daytime sleepiness (e.g., narcolepsy, idiopathic hypersomnia) in particular in children, adolescents and adults.
    Type: Application
    Filed: November 30, 2021
    Publication date: May 26, 2022
    Inventors: Alexander C. ZWYER, Lewis P. AMSEL, Virginia SCHMITH, Scott BRANTLEY
  • Mazindol IR/SR multilayer tablet and its use for the treatment of attention deficit/hyperactivity disorder (ADHD)
    Patent number: 11207271
    Abstract: The present invention relates to a modified-release composition of mazindol and its use in the treatment of attention deficit disorders (ADD) or attention deficit/hyperactivity disorder (ADHD) or related deficit of alertness (i.e., incoercible sleepiness) or decline of vigilance (i.e., daytime somnolence) or excessive daytime sleepiness (e.g., narcolepsy, idiopathic hypersomnia) in particular in children, adolescents and adults.
    Type: Grant
    Filed: March 8, 2017
    Date of Patent: December 28, 2021
    Assignee: NLS Pharmaceutics AG
    Inventors: Alexander C. Zwyer, Lewis P. Amsel, Virginia Schmith, Scott Brantley
  • A MAZINDOL IR/SR MULTILAYER TABLET AND ITS USE FOR THE TREATMENT OF ATTENTION DEFICIT/HYPERACTIVITY DISORDER (ADHD)
    Publication number: 20210038521
    Abstract: The present invention relates to a modified-release composition of mazindol and its use in the treatment of attention deficit disorders (ADD) or attention deficit/hyperactivity disorder (ADHD) or related deficit of alertness (i.e., incoercible sleepiness) or decline of vigilance (i.e., daytime somnolence) or excessive daytime sleepiness (e.g., narcolepsy, idiopathic hypersomnia) in particular in children, adolescents and adults.
    Type: Application
    Filed: March 8, 2017
    Publication date: February 11, 2021
    Inventors: Alexander C. ZWYER, Lewis P. AMSEL, Virginia SCHMITH, Scott BRANTLEY